Evaluation of the COBAS Amplicor HCMV monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation

Bone Marrow Transplantation

Volumn 38, Issue 1, 2006, Pages 53-60

  Lengerke, C ^a   Ljubicic, T ^a   Meisner, C ^b   Loeffler, J ^a   Sinzger, C ^a   Einsele, H ^a   Hebart, Holger ^a,c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Institute of Medical Information Processing   (Germany)

^c Center for Internal Medicine   (Germany)

Author keywords

Allogeneic stem cell transplantation; COBAS; Human cytomegalovirus; Risk factors; Viral load

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CYTOMEGALOVIRUS INFECTION; EARLY DIAGNOSIS; FEMALE; HEMATOLOGIC DISEASE; HERPES SIMPLEX; HIGH RISK PATIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE STATUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MONITOR; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RISK FACTOR; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; STEM CELL MOBILIZATION; VIREMIA; VIRUS CULTURE; VIRUS DETECTION; VIRUS LOAD;

ADULT; AGED; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; FEMALE; FIBROBLASTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD;

EID: 33745279068     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705408     Document Type: Article

References (49)

1. Emmanuel D, Cunningham L, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J et al. Cyomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988; 109: 777-782.
2. Ljungman P, Aschan J, Lewensohn-Fuchs I, Carlens S, Larsson K, Lonnqvist B et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell recipients. Transplantation 1998; 66: 1330-1334.
3. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human bone marrow transplantation. J Infect Dis 1998; 153: 478-488.
4. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD, Reed EC et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplantation. Ann Intern Med 1988; 109: 783-788.
5. Goodrich JM, Boeckh M, Bowden R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994; 19: 287-298.
6. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplantation. Ann Int Med 1993; 118: 173-178.
7. Li CR, Greenberg P, Gilbert MJ, Goodrich JM, Riddell SR. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994; 83: 1971-1979.
8. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV-infection. Bone Marrow Transplant 2000; 25: 757-763.
9. Caliendo AM, Schuurman R, Yen-Lieberman B, Spector SA, Andrsen J, Manjiry R et al. Comparison of quantitative and qualitative PCR assays for cytomegalovirus in plasma. J Clin Microbiol 2001; 39: 1334-1338.
10. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin SA (eds). Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Elsevier Science Publishers: Paris, 1993, pp 233-237.
11. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
12. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of HCMV infection after BMT as demonstrated by the PCR technique. Blood 1991; 77: 1104-1110.
13. Hebart H, Muller C, Loffler J, Jahn G, Einsele H. Monitoring of CMV infection: A comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation. Bone Marrow Transplant 1996; 17: 861-868.
14. Von Muller L, Hampl W, Hinz J, Meisel H, Reip A, Engelmann E et al. High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay. J Clin Microbiol 2002; 40: 2285-2287.
15. Boivin G, Quirk MR, Kringstad BA, Germain M, Jordan MC. Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leucocytes of immunocompromised patients. Antimicrob Agents Chemother 1997; 41: 860-862.
16. Saltzman RL, Qiurk MR, Jordan MC. High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients. J Clin Investig 1992; 90: 1832-1838.
17. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF et al. Early treatment with ganciclivir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325: 1601-1607.
18. Hebart H, Rudolph T, Loeffler J, Middeldorp J, Ljubicic T, Jahn G et al. Evaluation of the NucliSEns CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 181-187.
19. Hebart H, Wuchter P, Loeffler J, Gscheidle B, Hamprecht K, Sinzger C et al. Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant. Bone Marrow Transplant 2001; 28: 213-218.
20. Boeckh M, Bowden RA, Gooley T, Myerson D, Corey L. Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients (letter). Blood 1999; 93: 1781-1782.
21. Einsele H, Ehninger G, Steidle M, Vallbracht A, Muller M, Schmidt H et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991; 338: 1170-1172.
22. Gor D, Sabin C, Prentice HG, Vyas N, Man S, Griffiths PD et al. Longitudinal analysis in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21: 597-605.
23. Wolf DG, Spector S. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993; 56: 330-334.
24. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 1996; 88: 4063-4071.
25. Boivin G, Belanger R, Delage R, Beliveau C, Demers C, Goyette N et al. Quantitative analysis of cytomegalovirus (CMV) viremia using the pp65 antigenemia assay and the COBAS AMPLICOR CMV MONITOR PCR test after blood and marrow allogeneic transplantation. J Clin Microbiol 2000; 38: 4356-4360.
26. Flexman J, Kay J, Fonte R, Herrmann R, Gabbay E, Palladino S. Differences between the quantitative antigenemia assay and the Cobas amplicor monitor quantitative PCR assay for detecting the CMV viraemia in bone marrow and solid organ transplant patients. J Med Virol 2001; 64: 275-282.
27. Piiparinen H, Hockerstedt K, Lappalainen M, Suni J, Lautenschlager I. Monitoring of viral load by quantitative plasma-PCR during active cytomegalovirus infection of individual liver transplant patients. J Clin Microbiol 2002; 40: 2945-2952.
28. Aitken C, Barrett-Muir W, Millar C, Templeton K, Thomas J, Sheridan F et al. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation. J Clin Microbiol 1999; 37: 2804-2807.
29. Preiser W, Brauninger S, Schwerdtfeger R, Ayliffe U, Garson JA, Brinks NS et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001; 20: 59-70.
30. Pellegrin I, Garrigue I, Binquet C, Chene G, Neau D, Bonot P et al. Evaluation of new quantitative assays for diagnosis and monitoring of cytomegalovirus disease in human immunodeficiency virus-positive patients. J Clin Microbiol 1999; 37: 3124-3132.
31. Diaz-Mitoma F, Leger C, Miller H, Giulivi A, Frost R, Shaw L et al. Comparison of DNA amplification, mRNA amplification, and DNA hybridization techniques for detection of cytomegalovirus in bone marrow transplant recipients. J Clin Microbiol 2003; 41: 5159-5166.
32. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D et al. Randomized multicenter trial of foscarnet versus ganciclovir for the preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002; 99: 1159-1164.
33. Ordemann R, Naumann R, Geissler G, Kroshinsky F, Bornhauser M, Schwerdtfeger R et al. Foscarnet - an alternative for cytomegalovirus prophylaxis after allogeneic stem cell transplantation? Ann Hematol 2000; 79: 432-436.
34. Cope AV, Sabin C, Burroughs A, Rolles K, Griffiths PD, Emery VC. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176: 1484-1490.
35. Cope AV, Sweny P, Sabin C, Rees L, Griffiths PD, Emery VC. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997; 52: 200-205.
36. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a polymerase chain reaction: Correlation with disease. J Gen Virol 1995; 76: 309-319.
37. Sia IG, Wilson JA, Espy MJ, Paya CV, Smith TF. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 2000; 181: 717-720.
38. Roberts TC, Brennan DC, Buller RS, Gaudreault-Keener M, Schnitzler MA, Sternhell KE et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998; 178: 626-635.
39. Hassan-Walker AF, Kidd IM, Sabin C. Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: Relationship with donor/recipient serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 1999; 58: 182-187.
40. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355: 2032-2036.
41. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: Impact of host factors, drug therapy, and subclinical reactivation. Blood 2003; 102: 3060-3067.
42. Junghanss C, Storb R, Maris MB, Carter RA, Sandmaier BM, Maloney DG et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003; 123: 662-670.
43. Junghanss C, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002; 99: 1978-1985.
44. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
45. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin N Am 1995; 9: 1005-1044.
46. Grow WB, Moreb JS, Roque D, Marion K, Leather H, Reddy V et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant 2002; 29: 15-19.
47. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin N Am 1995; 9: 1045-1074.
48. Husni RN, Gordon SM, Longworth DL, Arroglia A, Stillwell PL, Avery RK et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-755.
49. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary infection. J Infect Dis 2002; 185: 273-282.